51
|
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Giordano M, Gori S, Garrone O, Bighin C, Venturini M. Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.528] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
52
|
Milella M, Sperduti I, Gelibter A, Bria E, Cianci G, Moscetti L, Mansueto G, Ruggeri E, Gamucci T, Cognetti F. 6598 Erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC): preliminary results from a multicenter phase II study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71319-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
53
|
Grande R, Cianci G, Grassi G, Sperduti I, Narducci F, Gelibter A, Nuzzo C, Mentuccia L, Giampaolo M, Gamucci T. 6056 Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer (mCRC) patients (pts): is efficacy mantained? EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71151-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
54
|
Gamucci T, Narducci F, Sperduti I, Mentuccia L, Trapasso T, Magnolfi E, Grande R, Cianci G, Gemma D, Trombetta G. Evaluation of the Edmonton Symptoms Assesment Scale (ESAS) symptoms improvement (SI) assessment as a prognostic factor for survival in advanced cancer patients (pts) undergoing palliative care (PC): An observational prospective study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9591 Background: ESAS is a validated tool for physical symptoms assessment in PC practice which evaluates symptoms through a numeric scale ( 0–10). The use of SI as a prognostic factor is controversial. To this purpose, an observational prospective study in advanced cancer pts previously treated with anti-cancer treatments and now undergoing only PC was conducted. Methods: Pts were considered eligible if no longer able to receive any anticancer treatment; they were scheduled to undergo ESAS assessment: 1) at the hospitalization time-point (TH); 2) at the hospital discharge time-point (TD). Symptoms’ scores were divided into 3 severity-classes (SC): mild (0–3, MI), moderate (4–6, MO) and severe (≥7, S). Differences across symptoms’ classes between TH and TD was analyzed with the paired-data McNemar-test, according to tumor types. KM method was used for survival calculation, according to ESAS score classes, and logrank test for curves comparison. Uni/multi-variate survival analysis including age, sex, tumour, symptoms number and score class, PaP (Palliative Prognostic)-score, KPS, were carried out using the Cox regression model. Results: ESAS was administered to 68 pts, gastrointesinal (GI)/lung (NSCLC): 39/29, median age: 69-yrs, KPS ≤50/>50: 27 (39.7 %)/ 41 (60.3%), PaP-score A/B/C: 26 (38.2%)/37 (54.4%)/C (7.4%). A statistically significant reduction of S-SC rates was observed, as shown in the Table . SI correlates with survival improvement: PaP score (HR 2.95, 95% CI 1.35–6.41, p=0.006) and anorexia (HR 3.21, 95% CI 1.33–7.72, p=0.009) appear to be prognostic factors for survival at the multivariate analaysis for GI pts; asthenia is the only significant variable (HR 5.11 CI 95% 1.86–14.03, p=.0.002) for NSCLC pts. Conclusions: SI according to ESAS after PC treatment represents an important prognostic factor for survival in pts no longer suitable to receive any anticancer active therapies. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Gamucci
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - F. Narducci
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - I. Sperduti
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - L. Mentuccia
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - T. Trapasso
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - E. Magnolfi
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - R. Grande
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - G. Cianci
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - D. Gemma
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| | - G. Trombetta
- Ospedale S.S. Trinità, Sora, Italy; Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
55
|
Gebbia V, Morena R, Frontini L, Aitini E, Daniele B, Gamucci T, Di Maio M, Morabito A, Gallo C, Gridelli C. The DISTAL-2 phase III randomized trial of single agent weekly docetaxel (wD) vs wD plus gemcitabine (G) or vinorelbine (V) vs wD plus capecitabine (X) as second-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
56
|
Del Mastro L, Clavarezza M, Amadori D, Garrone O, Mattioli R, Ponchio L, Latini L, Saracchini S, Fabi A, Gamucci T. Once-weekly epoetin beta treatment in anemic patients with breast cancer receiving chemotherapy: Interim analysis of a multicenter, single arm study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19605] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19605 Background: Epoetin beta administered three times weekly is effective in the treatment of anemia in patients with malignancy. This study investigated the efficacy and safety of a more convenient and reduced frequency administration of epoetin beta 30,000 IU sc once weekly in anemic patients with early or metastatic breast cancer receiving chemotherapy (CT). Methods: Patients >18 years with early or metastatic breast cancer receiving CT with hemoglobin (Hb) <11 g/dL were enrolled in this open-label, single-arm, multicenter study. Patients received epoetin beta until Hb was = 12 g/dL. The primary endpoint was the proportion of patients with an Hb increase =2 g/dL from baseline or achievement of Hb =12 g/dL after 12 weeks of treatment in the absence of transfusion. Other endpoints included: median time to response, median change in Hb level after 12 weeks of treatment from baseline and proportion of patients with a Hb increase =1 g/dL at week 4. Adverse events (AEs), vital signs, and laboratory safety were recorded. Results: Interim data are presented for 101 patients (out of 200 patients enrolled) who had completed treatment to date. Patients’ characteristics were: median age 58 years (33–81), PS 0–1 88%, metastatic disease 49%, median baseline Hb 10.1 g/dL (7.8–11.7). Overall, 46% (95% CI: 35.5–57.6) of patients responded according to the primary end point, the median time to response was 42 days (95%CI: 15–103). Secondary objectives: median Hb increase after 12 weeks was 1.7 g/dL (CI95%: -1.6 to +5.4), at week 4 an Hb rise =1 g/dL was observed in 44% of patients (CI95%: 33.0–57.4). Overall, 13/101 (13%) patients required red blood transfusions, the median number of transfusion was 2. The incidence of treatment-related AEs (6.9%) was consistent with the current label for epoetin beta. Conclusions: These preliminary results indicate that Epoetin beta 30,000 IU once weekly is effective and well tolerated in patients with early or advanced breast cancer receiving CT. [Table: see text]
Collapse
Affiliation(s)
- L. Del Mastro
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - M. Clavarezza
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - D. Amadori
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - O. Garrone
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - R. Mattioli
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - L. Ponchio
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - L. Latini
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - S. Saracchini
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - A. Fabi
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| | - T. Gamucci
- IST - Istituto Nazionale Ricerca Cancro, Genova, Italy; Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy; Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, Italy; Azienda Sanitaria U.S.L. 3, Fano, Italy; Fondazione Salvatore Maugeri, Pavia, Italy; Ospedale Generale Provinciale U.S.L. 9, Macerata, Italy
| |
Collapse
|
57
|
Cazzaniga ME, Mustacchi G, Pronzato P, Di Costanzo F, De Matteis A, Ravaioli A, Gamucci T, Brugia M, Bari M, Rulli E. Pathological characteristics and clinical outcome in triple-negative breast cancer (BC) patients (PTS): Results from the NORA study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11014 Background: Different studies have recently focused the attention on the so-called triple-negative pts, defined as ER-/PR- /HER2-. Although triple-negative tumours have been reported to be more aggressive, there are limited long-term data evaluating outcome as a function of this classification. Methods: NORA is an observational study aimed at investigating treatment modalities and clinical outcome of 3515 patients (pts) with early breast cancer (EBC) treated in 77 Oncological Centres in Italy from to 2000 to 2003, whose overall results have been already published. We now compare pathological characteristics and clinical outcome of pts for whom ER and PR andHER2 tests are negative with remaining pts (OTH). Results: 123 (4.1%) of 2968 evaluable pts resulted triple-negative. Out of these 123, 76 pts (61.7% vs 63.2% of OTH) were treated with conservative surgery (CS). Pathological T stage was T1 in55.3% pts (OTH: 59.6%), 47.9% were pN+ (OTH: 45.3%), 63.2 had G3 tumours (OTH: 34.1%). Chemotherapy alone was administered in 89.4% pts, mainly anthracycline-based (54.1%). At a median follow up of 27 months, all triple-negative pts were alive, 11 (8.9%) with relapse. No difference has been observed between two groups both in DFS (HR=0.74; 95%CI: 0.39–1.40; p=0.35) and OS (HR not estimated, p=0.99). Conclusions: Our results suggest that triple-negative pts have pathological characteristics similar to what observed in the other pts, receive CS in the same percentage of the cases, but have a 3-fold increase of undifferentiated tumours. On the contrary to what observed by other Authors, our data show that triple- negative pts do not have worse prognosis. Longer follow up is required to confirm these data. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. E. Cazzaniga
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - G. Mustacchi
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - P. Pronzato
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - F. Di Costanzo
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - A. De Matteis
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - A. Ravaioli
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - T. Gamucci
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - M. Brugia
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - M. Bari
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| | - E. Rulli
- Treviglio Hospital, Treviglio, Italy; University of Trieste, Trieste, Italy; Isituto Tumori, Genova, Italy; Ospedale Careggi, Firenze, Italy; Istituto Pascale, Napoli, Italy; Ospedale degli Infermi, Rimini, Italy; Ospedale Civile Umberto I, Frosinone, Italy; Az Osp S Maria, Terni, Italy; Osp Calvi, Noale, Italy; Istituto Mario Negri, Milano, Italy
| |
Collapse
|
58
|
Galligioni E, Gebbia V, Cartenì G, Gamucci T, Grossi F, Ferraù F, Nardi M, Pollera C, Rossi S, De Marinis F. Randomized phase II trial of two sequential schedules of docetaxel (D) and cisplatin (C) followed by gemcitabine (G) in patients with advanced non-small cell lung cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18154 Background: C based doublets remain the cornerstone for first line treatment of advanced NSCLC but the role of sequential use of chemotherapy is still investigational. Aim of this study was to assess the activity and toxicity of 3 courses of C and D followed by 3 courses of single agent G, to reduce C exposure and sequentially administer 2 second generation cytotoxic drugs. The weekly D/C schedule was further investigated, to reduce toxicity. Methods: Chemotherapy naive stage IIIB or IV measurable NSCLC pts, aged 18–70 and PS 0–1, were stratified by stage (IIIB vs IV) and randomized, after local ethic committee approval and signed informed consent, to D and C (both 75 mg/m2 on day 1) q21 days for 3 cycles (Arm A), or to D and C (both 25 mg/m2 on days 1, 8, 15) q28 days for 3 (Arm B). Responding or stable pts of each arm, were treated with 3 additional cycles of G (1,200 mg/m2 on days 1, 8) q 21 days. Primary endpoint of the study was response rate (RECIST). Sample size was calculated of 42 pts per arm, considering worthy of further investigation a regimen with =14 objective responses. Results: Between May 2005 and October 2006, 88 pts were enrolled (Arm A/B: 43/45), with 69 evaluable so far (median age 63 yrs, median PS 0, and M/F ratio 53/16). Toxicity (NCI-CTG criteria) after 3 cycles, evaluable on 67 (32/35) pts, was mainly hematological, with grade 3/4 neutropenia in 17 pts (17/0), neutropenic fever in 1 (arm A), infections in 2 (arm B), grade 3/4 thrombocytopenia in 3 (1/2) and grade 3/4 anemia in 2 (arm A). Non-hematological grade 3/4 toxicity consisted of fatigue (4/1), diarrhea (4/1), pulmonary toxicity (1/4), pain (2/3), stomatitis (1/2) and alopecia (2/0). Fifty one pts (A/B: 29/22) are evaluable for response after 3 cycles, with 16 PR (55%) and 7NC in arm A and 1CR+6PR (32%) and 7NC in arm B. Objective responses after 6 cycles, available only in few pts so far, show 1CR+10PR in arm A and 2PR in arm B. At a median FU of 6.5 months, 60/85 pts are alive (33/27) and 25 are dead (8/17), with 3 pts, never treated, lost to f. up. Conclusions: From these preliminary results, CD combination appears active and manageable while the activity of G, cannot be defined yet. Data collection is continuing and analysis will be completed and mature, by the time of the meeting. [Table: see text]
Collapse
Affiliation(s)
- E. Galligioni
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - V. Gebbia
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - G. Cartenì
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - T. Gamucci
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - F. Grossi
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - F. Ferraù
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - M. Nardi
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - C. Pollera
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - S. Rossi
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| | - F. De Marinis
- St. Chiara Hospital, Trento, Italy; Dipartimento Oncologico La Maddalena, Palermo, Italy; A. Cardarelli Hospital, Napoli, Italy; S.S. Trinità Hospital, Frosinone, Italy; National Institute for Cancer Research, Genova, Italy; S. Vincenzo Hospital, Taormina (ME), Italy; Bianch Melacrino Morelli Hospital, Reggio Calabria, Italy; Belcolle Hospital, Viterbo, Italy; Sanofi-Aventis, Milano, Italy; S. Camillo-Forlanini Hospital, Roma, Italy
| |
Collapse
|
59
|
Di Maio M, Gallo C, Barbera S, Ceribelli A, Gamucci T, Isa L, Piazza E, Borsellino N, Zagonel V, Gridelli C. Two-drug gemcitabine-based first-line treatment of elderly patients (pts) with small cell lung cancer (SCLC): The G-STEP program. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7089 Background: Trials testing chemotherapy for elderly pts with SCLC are scanty. Gemcitabine (Gem) is active and well tolerated. The G-STEP program looked for optimal 2-drug combination of G with either vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car). Methods: Extended stage SCLC pts, aged >70 years, PS 0–2, were eligible. Dose of G was 1,000 mg/m2, dd 1&8, every 3 weeks in all the four combinations. As safety data in the elderly were already available for Gem+Vin (Vin dose 25 mg/m2, dd 1&8), a two-stage minimax flexible design was applied with response as end-point: ≥13 responses/30 pts required at 1st stage, with p0=0.40, p1=0.60, α and β=0.10. For Gem+Car, Gem+Cis, Gem+Eto a phase 1–2 Bayesian design to select optimal dose was applied (Thall & Russell, Biometrics, 1998), with 3 possible outcomes for each patient: “active” (response and no unacceptable toxicity [UT]), “inactive” (no response, no UT), or “toxic” (UT independently of response). A response rate [RR] ≥60% and a rate of UT ≤25% were acceptable. Dose levels to explore were: Car: AUC 3.5 / 4 / 4.5, d1; Cis: 50 / 60 / 70 mg/m2, d1; Eto: 60 / 70 / 80 mg/m2, dd 1,2,3. Results: From May 2000 to September 2005, 78 eligible pts were enrolled; median age was 74 years (42% of pts older than 75yrs). In the whole group, median progression-free survival and overall survival were 20.3 weeks (95% CI 17.6 - 24.1) and 33.7 weeks (95% CI 23.7 - 41.6), respectively. Study of Gem+Vin was closed for inactivity after 1st stage with 11 responses / 30 pts (RR 36.7%, 95% exact CI: 19.9–56.1). Gem+Eto arm was closed after 10 pts (5 inactive and 5 toxic) because too high probability (0.994) of inactivity. Gem+Cis arm was closed after 12 pts (2 active, 5 inactive, 5 toxic) because too high probability (0.988) of inactivity. With Gem+Car (December 2005: 2 pts ongoing, 24 analysed: 12 active, 6, inactive and 6 toxic), RR in the 20 pts receiving Car at AUC 3.5 was 60% (95% exact CI: 36.1–80.9). Conclusions: The combination of gemcitabine and carboplatin seems promising for future trials in elderly patients with extended SCLC. The G-STEP program was supported by GIOGER. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Di Maio
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - C. Gallo
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - S. Barbera
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - A. Ceribelli
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - T. Gamucci
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - L. Isa
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - E. Piazza
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - N. Borsellino
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - V. Zagonel
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| | - C. Gridelli
- National Cancer Institute, Naples, Italy; Second University of Naples, Naples, Italy; Mariano Santo Hospital, Cosenza, Italy; Regina Elena Institute, Rome, Italy; Umberto I Hospital, Frosinone, Italy; Serbelloni Hospital, Gorgonzola (MI), Italy; Luigi Sacco Hospital, Milan, Italy; Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy; San Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy; San Giuseppe Moscati Hospital, Avellino, Italy
| |
Collapse
|
60
|
Pollera CF, Nelli F, Gamucci T, Sperduti I, Giampaolo AM, Moscetti L, Tonini G, Mentuccia L, Nardi M, Cortesi E. Prospective evaluation of epoetin-alfa (EA) vs epoetin-beta (EB) vs darbepoetin (DE) in anemic cancer patients (pts) receiving chemotherapy (CT): Early results of an independent observational survey by the Italian ReVERTO network. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18548 Background: Direct comparison of EA vs EB vs DE has never been performed. In order to define the efficacy, impact on quality of life (QL) and pt’s preference, a prospective observational comparison of erythropoietic agents has been carried out. Methods: Anemic pts (hgb <11 gr/dL) scheduled to receive at least 3 cycles of CT were stratified according to 5 factors (platinum-based CT vs non-platinum; hgb ≤9,5 vs >9,5; PS ≤0–1 vs >1; previous CT vs upfront CT; and previous antianemic therapy vs not) and were autonomously assigned by 15 investigators to EA (3 times a week) or EB (3 times a week and only in pts receiving platinum-based CT) or DE (once a week) therapy. Efficacy by hgb level changes and transfusion needing was evaluated after each cycle of CT, QL by Fact-An questionnaire after 1 and 3 cycles of CT, and pt’s preference for standard vs weekly schedule at least once thereafter. Results: From 09/04 to 12/05 177 pts were recruited: 41%, 39% and 20% were assigned to DE, EA and EB, respectively. Severe anemia at baseline (≤9,5) was reported in 29% of pts, whereas 47% received platinum-based CT. Stratifying categories were well balanced among the treatment groups. Baseline mean hgb values were 9.7, 9.9, and 10 for DE, EA and EB, respectively. As of the general population, DE produced higher subsequent mean hgb increase in respect to EA and EB (Mean increase [gr/dL] for DE: 0.84, 1.58, 2.03; EA: 0.34, 0.84, 1.68; EB: 0.76, 1.54, 1.17). No difference was observed neither among pts receiving platinum-based CT, (mean increase: DE: 0.34, 1.76, 2.8; EA: 0.7, 1.27, 2.14; EB: 0.76, 1.54, 1.71) nor among pts with severe anemia at baseline (DE: 0.98, 2, 2.6; EA: 1.24, 1.94, 3.13; EB: 1.25, 2.25, 2.75). Transfusion needing ranged from 7% for DE to 3% for EB without any significant difference. To date 67% of pts completed at least one subsequent QL valuation, whereas 62% gave their preference for treatment schedule. Conclusions: Early results of our prospective analysis show that antianemic therapy with D is at least as effective as standard schedule of EA or EB. Efficacy of DE seems confirmed in pts with bad prognostic categories for anemia. Major data on QL and pt’s preference will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. F. Pollera
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - F. Nelli
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - T. Gamucci
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - I. Sperduti
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - A. M. Giampaolo
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - L. Moscetti
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - G. Tonini
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - L. Mentuccia
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - M. Nardi
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| | - E. Cortesi
- Ospedale Belcolle - ASL di Viterbo, Viterbo, Italy; Ospedale, Sora, Italy; National Cancer Institute, Rome, Italy; Campus Bio-Medico University, Rome, Italy; University La Sapienza, Rome, Italy; Ospedali Riuniti, Reggio Calabria, Italy
| |
Collapse
|
61
|
Gridelli C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carrozza F, Favaretto A, Daniele B, Galetta D, Morabito A. A factorial phase III randomized trial of rofecoxib and prolonged constant infusion of gemcitabine at 10mg/m 2/min (PCI-G) in first-line treatment of adult patients (pts) with advanced non-small cell lung cancer (NSCLC): The GECO study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7069 Background: Preclinical and clinical evidence suggest that rofecoxib and PCI-G might improve efficacy of treatment of advanced NSCLC. Methods: Advanced (stage IV or IIIb with supraclavear nodes or pleural effusion) NSCLC pts, aged <70, PS 0–1, were eligible. A 2x2 factorial design was applied to test if addition of rofecoxib (50 mg daily) or PCI-G could improve overall survival (OAS) compared with standard first-line treatment [cisplatin (80 mg/m2 d 1) and gemcitabine (1200 mg/m2 dd 1&8) every 21 days]. To have 80% power of detecting a 0.67 HR of death, with bilateral alpha = 0.05, 400 pts were planned and 200 deaths were required for each comparison. Response was assessed with RECIST, quality of life (QoL) by EORTC questionnaires. Results: From Jan ’03 to May ’05, 400 pts were enrolled. Rofecoxib arms were closed (Oct 1st,’04) due to manufacturer decision of drug withdrawing for safety issues. As of Dec ’05, analyses include 400 pts (246 deaths) for PCI-G and 240 pts (enrolled as of Jul 1st,’04 to have a 3-month chance of treatment) for rofecoxib comparison (168 deaths). Median age was 60. PCI-G did not improve OAS (median 47.3 vs 42.9 weeks with standard infusion, HR 0.97, 95% CI 0.75–1.25), nor any other secondary end-point. Rofecoxib did not prolong OAS (median 43.6 vs 44.1 weeks without rofecoxib, HR 1.01, 95% CI 0.74–1.38), but improved response rate (41.2% vs 26.4%, p = 0.02), global QoL, physical and role functioning, fatigue, pain and analgesic consumption. In both comparisons, there was no clinically relevant difference in toxicity. Conclusions: Neither PCI-G nor rofecoxib prolonged OAS. Rofecoxib improved response rate and several QoL items, including pain-related and global QoL. Partially supported by AIRC; rofecoxib freely supplied by MS&D Italy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Gridelli
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - A. Ceribelli
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - V. Gebbia
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - T. Gamucci
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - F. Ciardiello
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - F. Carrozza
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - A. Favaretto
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - B. Daniele
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - D. Galetta
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| | - A. Morabito
- San Giuseppe Moscati Hospital, Avellino, Italy; Regina Elena Institute, Rome, Italy; La Maddalena Hospital, Palermo, Italy; Umberto I Hospital, Frosinone, Italy; II University, Naples, Italy; Cardarelli Hospital, Campobasso, Italy; Civil Hospital, Padova, Italy; Rummo Hospital, Benevento, Italy; Oncologic Institute, Bari, Italy; National Cancer Institute, Naples, Italy
| |
Collapse
|
62
|
Mariani P, Moliterni A, Da Prada G, Hess D, Gamucci T, Zaniboni A, Malossi A, Barbieri P, Marsoni S, Gianni L. A phase II trial of the novel oral camptothecin gimatecan (G) in women with anthracycline (A) and taxane (T) pre-treated advanced breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.662] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
662 Background: Gimatecan (G) is a new oral camptothecin with a favourable therapeutic index in several tumor xenograft models and with documented antitumor activity in breast, endometrial and NSCLC cancer in Phase I. A Phase II trial was implemented to determine the antitumor activity of G in women with pre-treated metastatic breast cancer (MBC). Methods: A Simon 2-step design was used: patients with MBC who failed A & T were eligible. Treatment failure was defined as disease progressing after receiving both A and T (adjuvant or metastatic setting). All patients had ECOG 0–1. Baseline neuropathy > gr 1 or CNS metastases were criteria of exclusion. G was administered for 5 days every week on weeks 1 & 2 q4weeks at 4–5 mg/m2 total dose per cycle. Results: To date, 21 patients have received 67 cycles of G (median 3); 18 are evaluable for the 1st step analysis. Median age was 53 years (range, 32–70), all had received A & T prior treatment. The initial dose of 5 mg/m2 was reduced to 4 mg/m2 after treating the first 7 cases due to hematological toxicity (thrombocytopenia G3 30% and neutropenia G3–4 40%) that prevented the planned monthly retreatment. The toxicity at 4 mg/m2 included thrombocytopenia (% of cycles with any grade: 36%, G3 9%); neutropenia (G3 18%), diarrhea (1 case), nausea (81%, G3 18%), vomiting (G1 18%), and asthenia (G1 36%). To date, three confirmed partial responses (PR) lasting respectively 5.5, 5.7+, and 9.4+ months and two unconfirmed PR were observed in visceral and nodal sites. Accrual into step 2 is proceeding. Conclusions: Gimatecan at a dose of 4 mg/m2 is well tolerated and active. The antitumor activity of 27% observed in the first step of the study is unusual for camptothecins and prompted to continue to the second step and complete the ongoing enrolment of 43 patients overall. [Table: see text]
Collapse
Affiliation(s)
- P. Mariani
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - A. Moliterni
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - G. Da Prada
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - D. Hess
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - T. Gamucci
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - A. Zaniboni
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - A. Malossi
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - P. Barbieri
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - S. Marsoni
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| | - L. Gianni
- Istituto Nazionale dei Tumori, Milano, Italy; Fondazione Savatore Maugeri, Pavia, Italy; Kantonsspital St. Gallen, St. Gallen, Switzerland; Ospedale Umberto I, Frosinone, Italy; Casa di Cura Poliambulanza, Brescia, Italy; Ospedale degli Infermi, Biella, Italy; Sigma Tau S.p.A., Pomezia (Roma), Italy; Southern Europe New Drug Organization (SENDO), Milano, Italy
| |
Collapse
|
63
|
Mansueto G, Gareri R, Buccilli A, Trapasso T, Giampaolo M, Gamucci T. P-531 Treatment of anemia in elderly patients receiving first-line chemotherapy for advanced lung cancer: Analysis of an unselected population. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81024-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
64
|
Ferraresi V, Giampaolo MA, Gabriele A, Mansueto G, Buccilli A, Giannarelli D, Ciccarese M, Gamucci T. Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. J Exp Clin Cancer Res 2005; 24:187-96. [PMID: 16110750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
The aim of the current study was to evaluate the activity and toxicity of a combination of oxaliplatin with bolus fluorouracil and leucovorin in colorectal cancer (CRC) patients pretreated for advanced disease with various schedules including continuous fluorouracil infusion. Thirty consecutive patients with pretreated advanced CRC received oxaliplatin 130 mg/m2 by 2-h infusion dl, leucovorin 100 mg/m2 by 1-h infusion followed by fluorouracil 425 mg/m2 i.v. bolus from day 1 to 3 every 3 weeks for a maximum of 6 cycles. The best overall response rate in an intent-to-treat analysis was 13% (2 complete responses and 2 partial responses) (95% CI, 1.2-25.5%) and 37% of patients obtained stable disease with a tumor growth control rate of 50% (95% CI, 32.1-67.9%). The median progression-free survival was 4.0 months (95% CI, 1.4-6.5 months) and median overall survival was 12.0 months (95% CI, 9.9-14.1 months). The independent prognostic factors for improved overall survival were a good performance status and a response/stabilization of disease to chemotherapy. Severe neutropenia was quite common (43.3% of patients and 14.4% of cycles), although complicated by fever only in one case (3.3% of patients). There was one toxic death. In conclusion, the study combination showed an interesting rate of tumor growth control in a cohort of patients previously treated for advanced disease with various schedules including continuous fluorouracil infusion.
Collapse
Affiliation(s)
- V Ferraresi
- Dept. of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
65
|
Pollera CF, Moscetti L, Nelli F, Cortesi E, D'Auria G, De Pasquale Ceratti A, Gamucci T, Mansueto G, Ceribelli A, Felici A. First treatment choice for patients (pts) with advanced Non-Small-Cell Lung Cancer (NSCLC) presenting with brain metastasis (BM): A preliminary report of a multi-institutional survey. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. F. Pollera
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - L. Moscetti
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - F. Nelli
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - E. Cortesi
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - G. D'Auria
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - A. De Pasquale Ceratti
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - T. Gamucci
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - G. Mansueto
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - A. Ceribelli
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| | - A. Felici
- Belcolle Hospital ASL Viterbo, Viterbo, Italy; University La Sapienza, Rome, Italy; ASL Frosinone, Frosinone, Italy; Regina Elena Institute, Rome, Italy
| |
Collapse
|
66
|
Zeuli M, Gelibter A, Nardoni C, Gamucci T, Gabriele A, Pollera CF, Di Costanzo F, Signorelli C, Ferraresi V, Cognetti F. A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3748] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Zeuli
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - A. Gelibter
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - C. Nardoni
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - T. Gamucci
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - A. Gabriele
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - C. F. Pollera
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - F. Di Costanzo
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - C. Signorelli
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - V. Ferraresi
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| | - F. Cognetti
- Regina Elena National Cancer Institute, Rome, Italy; Ospedale SS. Trinità, Sora (FR), Italy; Medical Oncology, Belcolle Hospital, Viterbo, Italy; Azienda Ospedale Careggi, Firenze, Italy
| |
Collapse
|
67
|
Boni C, Gamucci T, Bonetti A, Bisagni G, Dall'o' E, Zanna C, Marsoni S, Sessa C. A phase II study of the novel oral camptothecin ST1481 in pretreated metastatic colorectal cancer (CRC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3684] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Boni
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| | - T. Gamucci
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| | - A. Bonetti
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| | - G. Bisagni
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| | - E. Dall'o'
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| | - C. Zanna
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| | - S. Marsoni
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| | - C. Sessa
- Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy; Ospedale SS. Trinità, Sora (Fr), Italy; AULSS21, Legnago (Vr), Italy; Southern Europe New Drugs Organization (SENDO), Milano, Italy; Sigma-Tau S.p.A., Pomezia (Roma), Italy; Ist. Oncologico della Svizzera Italiana - SENDO, Bellinzona, Switzerland
| |
Collapse
|
68
|
Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 2004; 40:1021-30. [PMID: 15093577 DOI: 10.1016/j.ejca.2004.01.014] [Citation(s) in RCA: 121] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2004] [Accepted: 01/21/2004] [Indexed: 11/12/2022]
Abstract
The potential value of baseline health-related quality-of-life (HRQOL) and clinical factors in predicting prognosis was examined using data from an international randomised phase III trial which compared doxorubicin and paclitaxel with doxorubicin and cylophosphamide as first line chemotherapy in 275 women with metastatic breast cancer. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the related breast module (QLQ-BR23) were used to assess baseline HRQOL data. The Cox proportional-hazards regression model was used for both univariate and multivariate analyses of survival. In the univariate analyses, performance status (P<0.001) and number of sites involved (P=0.001) were the most important clinical prognostic factors. The HRQOL variables at baseline most strongly associated with longer survival were better appetite, physical and role functioning, as well as less fatigue (P<0.001). The final multivariate model retained performance status (P<0.001) and appetite loss (P=0.005) as the variables best predicting survival. Substantial loss of appetite was the only independent HRQOL factor predicting poor survival and was strongly correlated (/r/>0.5) with fatigue, role and physical functioning. In addition to known clinical factors, appetite loss appears to be a significant prognostic factor for survival in women with metastatic breast cancer. However, the mechanism underlying this association remains to be precisely defined in future studies.
Collapse
Affiliation(s)
- F Efficace
- EORTC Data Centre, Quality of Life Unit, Avenue E. Mounier, 83-1200 Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
69
|
Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pellicciotta M, Ceribelli A, De Marco S, Facciolo F, Cognetti F. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res 2004; 23:25-32. [PMID: 15149147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably active regimen in advanced non-small cell lung cancer (NSCLC). This study was designed to evaluate the maximum tolerated dose (MTD) of a fixed dose of carboplatin with an area under the curve (AUC) of 6 and escalating doses of weekly paclitaxel with an initial dose of 50 mg/m2 with 10 mg/m2 increments at each level in untreated NSCLC patients (phase I study). The study continued with a phase II study. Thirty patients entered the phase I study. The MTD was: carboplatin AUC = 6 on days 1 and 28 plus paclitaxel 100 mg/m2 (1 hour) on days 1, 8,15, 28. The dose-limiting toxicity (DLT) was severe neutropenia and cardiological toxicity. Subsequently, 42 patients entered the phase II study with the same treatment schedule. The 2-drug combination was globally well tolerated. The overall response rate (RR) was 42% [CI 95%: 26.3-57.7], stable disease (SD) 29% and progression (PD) 29%. The median duration of response was 8.0 mos (range: 1.0-19.0). The median time to progression was 8.0 mos (range: 7.0-19.0) and the median survival was 14.0 months (range: 9.0-19.0). The association of carboplatin AUC = 6 and weekly paclitaxel 100 mg/m2 proved to be manageable, active and extremely safe even in elderly patients (one third of all patients in our cohort). The survival results were interesting: the median survival time was 14 months (9-19 months) and the 1- and 2-year survival was 59% and 16%, respectively.
Collapse
Affiliation(s)
- A Fabi
- Dept. of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
70
|
Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P, Piccart MJ. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2004; 39:2439-49. [PMID: 14602130 DOI: 10.1016/s0959-8049(03)00601-4] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Liver metastases have long been known to indicate an unfavourable disease course in breast cancer (BC). However, a small subset of patients with liver metastases alone who were treated with pre-taxane chemotherapy regimens was reported to have longer survival compared with patients with liver and metastases at other sites. In the present study, we examined the clinical outcome of breast cancer patients with liver metastases alone in the context of two phase III European Organisation for Research and Treatment of Cancer (EORTC) trials which compared the efficacy of doxorubicin (A) versus paclitaxel (T) (trial 10923) and of AC (cyclophosphamide) versus AT (trial 10961), given as first-line chemotherapy in metastatic BC patients. The median follow-up for the patients with liver metastases was 90.5 months in trial 10923 and 56.6 months in trial 10961. Patients with liver metastases alone comprised 18% of all patients with liver metastases, in both the 10923 and 10961 trials. The median survival of patients with liver metastases alone and liver plus other sites of metastases were 22.7 and 14.2 months (log rank test, P=0.002) in trial 10923 and 27.1 and 16.8 months (log rank test, P=0.19) in trial 10961. The median TTP (time to progression) for patients with liver metastases alone was also longer compared with the liver plus other sites of metastases group in both trials: 10.2 versus 8.8 months (log rank test, P=0.02) in trial 10923 and 8.3 versus 6.7 months (log rank test, P=0.37) in trial 10961. Most patients with liver metastases alone have progression of their disease in their liver again (96 and 60% of patients in trials 10923 and 10961, respectively). Given the high prevalence of breast cancer, improved detection of liver metastases, encouraging survival achieved with currently available cytotoxic agents and the fact that a significant portion of patients with liver metastases alone have progression of their tumour in the liver again, a more aggressive multimodality treatment approach through prospective clinical trials seems worth exploring in this specific subset of women.
Collapse
Affiliation(s)
- G Atalay
- Institut Jules Bordet, Boulevard de Waterloo 125, 1000 Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D, Cognetti F. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003; 14:1378-82. [PMID: 12954576 DOI: 10.1093/annonc/mdg360] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer. The aim of this phase II study is to determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced non-pretreated colorectal cancer. PATIENTS AND METHODS Forty-three chemotherapy-naïve patients were enrolled. Capecitabine 2500 mg/m(2)/day was administered orally twice a day continuously for 14 days and oxaliplatin 120 mg/m(2) was administered as a 2-h infusion on day 1, repeated every 3 weeks. RESULTS Forty-three patients were assessable for toxicity and 39 for clinical activity: the main toxicity was grade 3 or 4 diarrhea, which occurred in 28% of the patients. The response rates were 44% [95% confidence interval (CI), 29.3% to 59.0%] and 48.7% (95% CI 33.0% to 64.4%) (intention-to-treat and per protocol analysis, respectively). The median overall survival was 20 months (95% CI 12-28). CONCLUSIONS Combining capecitabine and oxaliplatin yields promising activity in advanced colorectal cancer; therefore, the capecitabine dose we utilized is probably too high. The main toxicity is diarrhea, which is manageable with appropriate dose reductions. This combination may be preferable compared to a standard combination with infusional fluorouracil/leucovorin as it is more convenient and practical with similar efficacy. Thus, phase III trials are needed to clarify its role in the treatment of chemotherapy-naïve advanced colorectal cancer patients.
Collapse
Affiliation(s)
- M Zeuli
- Department of Medical Oncology A, Regina Elena Cancer Institute, Roma, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
72
|
Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, Paoletti X, Hermans C, Lacombe D, Fumoleau P. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur J Cancer 2003; 39:330-4. [PMID: 12565985 DOI: 10.1016/s0959-8049(02)00559-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
XR5000 is a tricyclic carboxamide-based cytotoxic agent that binds to DNA by intercalation and stimulates DNA cleavage by inhibition of both topoisomerase I and II. The aim of this study was to evaluate the antitumoral activity and safety profile of XR5000 given as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Patients received XR5000 at the dose of 3010 mg/m(2) as a 120-h central venous infusion every 3 weeks. The 15 patients (median age 56 years, range 48-71 years) enrolled had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (3 patients), 1 (11 patients) or 2 (1 patient). A total of 32 cycles of XR5000 (median 2, range 1-6) were given to 14 patients. No objective response (assessed according to World Health Organization (WHO) criteria) was documented in the 12 evaluable patients by an external review panel; in 4 out of the 12 patients disease stabilisation was recorded. The following toxicities graded according to the Common Toxicity Criteria (CTC) version 2.0. were observed: one grade 3 and two grade 4 granulocytopenia, one grade 3 and one grade 4 thrombocytopenia, one grade 3 deep venous thrombosis, one grade 3 fatigue, and grade 3 undocumented epileptic seizures which led to death in 2 patients. With only 4 out of 12 patients reaching stable disease when using this dose and regimen, further evaluation of XR5000 in advanced NSCLC is not justified.
Collapse
Affiliation(s)
- C Dittrich
- Ludwig Boltzmann-Institute for Applied Cancer Research, (LBI-ACR VIEnna), Kaiser Franz Josef-Spital, 3rd Medical Department-Oncology, Kundratstrasse 3, 1100, Vienna, Austria.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
73
|
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20:3114-21. [PMID: 12118025 DOI: 10.1200/jco.2002.11.005] [Citation(s) in RCA: 181] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
PURPOSE To compare the efficacy and tolerability of the combination of doxorubicin and paclitaxel (AT) with a standard doxorubicin and cyclophosphamide (AC) regimen as first-line chemotherapy for metastatic breast cancer. PATIENTS AND METHODS Eligible patients were anthracycline-naive and had bidimensionally measurable metastatic breast cancer. Two hundred seventy-five patients were randomly assigned to be treated with AT (doxorubicin 60 mg/m(2) as an intravenous bolus plus paclitaxel 175 mg/m(2) as a 3-hour infusion) or AC (doxorubicin 60 mg/m(2) plus cyclophosphamide 600 mg/m(2)) every 3 weeks for a maximum of six cycles. A paclitaxel (200 mg/m(2)) and cyclophosphamide (750 mg/m(2)) dose escalation was planned at cycle 2 if no grade >or= 3 neutropenia occurred in cycle 1. The primary efficacy end point was progression-free survival (PFS). Secondary end points were response rate (RR), safety, overall survival (OS), and quality of life. RESULTS A median number of six cycles were delivered in the two treatment arms. The relative dose-intensity and delivered cumulative dose of doxorubicin were lower in the AT arm. Dose escalation was only possible in 17% and 20% of the AT and AC patients, respectively. Median PFS was 6 months in the two treatments arms. RR was 58% versus 54%, and median OS was 20.6 versus 20.5 months in the AT and AC arms, respectively. The AT regimen was characterized by a higher incidence of febrile neutropenia, 32% versus 9% in the AC arm. CONCLUSION No differences in the efficacy study end points were observed between the two treatment arms. Treatment-related toxicity compromised doxorubicin-delivered dose-intensity in the paclitaxel-based regimen
Collapse
Affiliation(s)
- L Biganzoli
- Investigational Drug Branch for Breast Cancer, European Organization for the Research and Treatment of Cancer Data Center, and Jules Bordet Institute, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
74
|
Silvestris N, Crucitta E, Lorusso V, Gamucci T, De Lena M. AIDS-related non-Hodgkin's lymphoma: Clinico-pathological characteristics and therapeutic strategies (Review). Int J Oncol 2002. [DOI: 10.3892/ijo.20.3.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
75
|
Schellens JHM, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Invest New Drugs 2002; 20:83-93. [PMID: 12003197 DOI: 10.1023/a:1014454821885] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic profile in a larger population, to estimate individual pharmacokinetic parameters and to investigate relationships with clinical outcome. A sparse sampling method was applied during course one, which involved two sampling time-points. A Bayesian algorithm was used to estimate individual pharmacokinetic parameters, in particular total plasma clearance (CL) and volume of distribution. In total, samples were collected of 109 (63%) of 173 patients. Pharmacokinetic-dynamic evaluation could be carried out successfully in 85 (78%) of the sampled patients. CL of lurtotecan showed substantial variability (mean 87 +/- 28 L/h) and was of the same magnitude as in the phase I studies where full pharmacokinetic curves were used. Residual variability in the population estimate of CL was 9.9%. No significant relationships were observed between exposure parameters and toxicity nor likelihood of tumor response, however the latter relationship may well have been obscured by the heterogeneity of the studied population. Prospective implementation of large scale population pharmacokinetic-dynamic analysis is feasible and important to establish whether interpatient variability in drug exposure is a major determinant of toxicity or activity.
Collapse
Affiliation(s)
- J H M Schellens
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Serrone L, Zeuli M, Gamucci T, Nardi M, Cognetti F. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemother Pharmacol 2001; 47:206-10. [PMID: 11320663 DOI: 10.1007/s002800000219] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
PURPOSE The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS). METHODS Since November 1995, 22 chemotherapy-naive patients have been treated. HD-IFO was given as a continuous infusion at a total dose of 14-18 g/m2 per cycle, with mesna, over 6 to 8 days, q 3 weeks, twice. EPI was administered subsequently as an i.v. bolus at a total dose of 120-160 mg/m2, on days 1-2, q 2 weeks, twice. G-CSF was planned for each course of treatment as a daily subcutaneous injection for 7 days, starting 24 h after the end of the treatment. After the first four cycles, patients were evaluated for surgery and patients with locally inoperable or metastatic disease received further chemotherapy up to a maximum of eight cycles. RESULTS The response of 19 patients could be assessed. One complete response (CR) and six partial responses (PRs) were achieved for an overall response rate of 37% (95% confidence interval, 15-59%). Noteworthy is that two of the six leiomyosarcoma patients responded to the HD-IFO treatment. The median survival period was 15 months. Most common toxicities included myelosuppression, nausea and vomiting, and stomatitis. Six patients were hospitalized for complicated nadir fever. No severe renal and CNS toxicities were seen. Transient gross hematuria occurred in six patients and affected treatment in only one case. There were no treatment-related deaths. CONCLUSIONS By the protraction of continuous infusion of HD-IFO over 6 to 8 days, ifosfamide-induced acute renal toxicity is avoided, while G-CSF support allows the delivery of the planned dose intensity in most of the patients. Although manageable in an oncology setting, the hematologic toxicity of such a regimen remains substantial. Moreover, in terms of efficacy and median survival, this regimen showed no benefits over a conventional-dose anthracycline-ifosfamide schema. Further evaluations of this novel ifosfamide-epirubicin schedule are not warranted, even if the HD-IFO regimen could be taken forward specifically for leiomyosarcomas in a phase II trial.
Collapse
Affiliation(s)
- L Serrone
- Division of Medical Oncology A, Regina Elena Institute for Cancer Research and Treatment, Via E. Chianesi, 53, 00144 Rome, Italy.
| | | | | | | | | |
Collapse
|
77
|
Gamucci T, Paridaens R, Heinrich B, Schellens JH, Pavlidis N, Verweij J, Sessa C, Kaye S, Roelvink M, Wanders J, Hanauske A. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann Oncol 2000; 11:793-7. [PMID: 10997805 DOI: 10.1023/a:1008373031714] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. PATIENTS AND METHODS Between April 1995 and November 1996, 67 eligible patients with pretreated breast cancer (25 patients) and chemo-naïve colorectal (19 patients) and non-small-cell lung cancer (23 patients) were entered into three multicentric, non-randomized phase II trials. Treatment schedule consisted of intravenous GI1147211 administered at a dose of 1.2 mg/m2/day for five consecutive days every three weeks. RESULTS Hematological toxicity was common with grade 3-4 neutropenia in 54% of patients and neutropenic fever together or not associated with infection in 14.5% of patients. Grade 3-4 thrombocytopenia and grade 2-4 anemia were observed in 20% and in 68% of patients, respectively. Non-hematological toxicity was generally mild to moderate and consisted mainly of gastrointestinal toxicity, asthenia and alopecia. A dose-escalation to 1.5 mg/m2/d was feasible in 17 (25%) patients. The antitumor activity of GI1147211 was moderate in breast cancer patients (3 partial responses (PRs), response rate (RR) 13%) and minimal in non-small cell lung cancer patients (2 PRs, RR 9%). No objective responses were obtained in colorectal patients. CONCLUSIONS GI147211, at the dose and schedule employed in this study, showed an acceptable safety profile but a modest antitumor activity in the examined tumor types.
Collapse
Affiliation(s)
- T Gamucci
- Division of Medical Oncology 1, Regina Elena Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
78
|
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000; 18:724-33. [PMID: 10673513 DOI: 10.1200/jco.2000.18.4.724] [Citation(s) in RCA: 283] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To compare the efficacy of paclitaxel versus doxorubicin given as single agents in first-line therapy of advanced breast cancer (primary end point, progression-free survival ¿PFS) and to explore the degree of cross-resistance between the two agents. PATIENTS AND METHODS Three hundred thirty-one patients were randomized to receive either paclitaxel 200 mg/m(2), 3-hour infusion every 3 weeks, or doxorubicin 75 mg/m(2), intravenous bolus every 3 weeks. Seven courses were planned unless progression or unacceptable toxicity occurred before the seven courses were finished. Patients who progressed within the seven courses underwent early cross-over to the alternative drug, while a delayed cross-over was optional for the remainder of patients at the time of disease progression. RESULTS Objective response in first-line therapy was significantly better (P =.003) for doxorubicin (response rate ¿RR, 41%) than for paclitaxel (RR, 25%), with doxorubicin achieving a longer median PFS (7.5 months for doxorubicin v 3.9 months for paclitaxel, P <.001). In second-line therapy, cross-over to doxorubicin (91 patients) and to paclitaxel (77 patients) gave response rates of 30% and 16%, respectively. The median survival durations of 18.3 months for doxorubicin and 15.6 months for paclitaxel were not significantly different (P =.38). The doxorubicin arm had greater toxicity, but this was counterbalanced by better symptom control. CONCLUSION At the dosages and schedules used in the present study, doxorubicin achieves better disease and symptom control than paclitaxel in first-line treatment. Doxorubicin and paclitaxel are not totally cross-resistant, which supports further investigation of these drugs in combination or in sequence, both in advanced disease and in the adjuvant setting.
Collapse
Affiliation(s)
- R Paridaens
- University Hospital Gasthuisberg, Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
79
|
Magnani E, Fabi A, Gamucci T, Saracino B, Rambone R, Mazza D, Vocaturo G, Cognetti F, Arcangeli G. Concomitant radiotherapy and chemotherapy given by protracted intravenous infusion as preoperative treatment in locally advanced cervical cancer. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81340-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
80
|
Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9:255-60. [PMID: 9602258 DOI: 10.1023/a:1008296622469] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Anemia is a common side effect of anticancer chemotherapy. Blood transfusion, previously the only available treatment for chemotherapy-induced anemia, may result in some clinical or subclinical adverse effects in the recipients. Recombinant human erythropoietin (rhEPO) provides a new treatment modality for chemotherapy-induced anemia. PATIENTS AND METHODS To evaluate the effect of rhEPO on the need for blood transfusions and on hemoglobin (Hb) concentrations, 227 patients with solid tumors and chemotherapy-induced anemia were enrolled in a randomized, controlled, clinical trial. Of 189 patients evaluable for efficacy, 101 received 5000 IU rhEPO daily s.c., while 88 patients received no treatment during the 12-week controlled phase of the study. RESULTS The results demonstrate a statistically significant reduction in the need for blood transfusions (28% vs. 42%, P = 0.028) and in the mean volume of packed red blood cells transfused (152 ml vs. 190 ml, P = 0.044) in patients treated with rhEPO compared to untreated controls. This effect was even more pronounced in patients receiving platinum-based chemotherapy (26% vs. 45%, P = 0.038). During the controlled treatment phase, the median Hb values increased in the rhEPO patients while remaining unchanged in the control group. The response was seen in all tumor types. CONCLUSIONS RhEPO administration at a dose of 5000 IU daily s.c. increases hemoglobin levels and reduces transfusion requirements in chemotherapy-induced anemia, especially during platinum-based chemotherapy.
Collapse
Affiliation(s)
- C Oberhoff
- Center for Gynecology and Obstetrics, University Hospital, Essen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
81
|
Paridaens R, Bruning P, Klljn J, Gamucci T, Biganzoli L, Van Vreckem A, Hoctin Boes G, Curran D, Piccart M. Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): An EORTC randomized study with crossover. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85218-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
82
|
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090-6. [PMID: 9164222 DOI: 10.1200/jco.1997.15.5.2090] [Citation(s) in RCA: 319] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE To assess activity and toxicity of topotecan in previously treated small-cell lung cancer (SCLC) patients. PATIENTS AND METHODS Patients with measurable SCLC, progressive after one first-line regimen, were eligible for the study. Two groups of patients were selected: (1) patients who failed first-line treatment < or = 3 months from chemotherapy discontinuation (refractory group); and (2) patients who responded to first-line treatment and progressed greater than 3 months after chemotherapy discontinuation (sensitive group). Topotecan was administered as a 30-minute daily infusion at a dose of 1.5 mg/m2 for 5 consecutive days, every 3 weeks. RESULTS One hundred one patients were entered onto the study and 403 courses were administered. Ninety-two patients (47 refractory and 45 sensitive) were eligible and assessable for response. Among refractory patients, there were two partial responses (PRs) and one complete response (CR), for an overall response rate of 6.4% (95% confidence interval [CI], 1.3% to 17.6%), whereas in the sensitive group, there were 11 PRs and six CRs, for an overall response rate of 37.8% (95% CI, 23.8% to 53.5%). Overall median duration of response was 7.6 months. Median survival was 5.4 months; median survival of refractory patients was 4.7 months, whereas that of sensitive patients was 6.9 months (P = .002). Median survival of responding patients was 12.5 months. Toxicity was mainly hematologic. Leukopenia, although short-lived, was universal, with grade III and IV neutropenia occurring in 28% and 46.8% of cycles, respectively. Nonhematological toxicity was mild. Fatigue/malaise was reported in 39.3% of cycles and transient elevation of liver enzymes in 17%. CONCLUSION Topotecan has significant activity in SCLC, particularly in patients sensitive to prior chemotherapy, with predictable and manageable toxicity. The incorporation of topotecan in combination chemotherapy regimens for future treatment of SCLC is warranted.
Collapse
Affiliation(s)
- A Ardizzoni
- Department of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
83
|
Piccart-Gebhart MJ, Bruning P, Gamucci T, Klijn J, Roy JA, Awada A, Kusenda Z, Van Vreckem A, Paridaens R. An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer. Semin Oncol 1996; 23:11-5. [PMID: 8893893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The activity of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in advanced breast cancer patients who have failed doxorubicin treatment is well established, but the optimal sequence between these two important agents remains to be determined. The European Organization for Research and Treatment of Cancer therefore designed a prospective randomized clinical trial in which patients not exposed to anthracyclines in the adjuvant setting received either first-line paclitaxel, given as a 3-hour infusion at a dose of 200 mg/m2 followed at the time of disease progression by second-line doxorubicin, given as a bolus injection at a dose of 75 mg/m2 or the reverse sequence. The target accrual is 330 patients. Interim results on 207 evaluable patients of 289 randomized are presented.
Collapse
|
84
|
Dirix LY, Tonnesen F, Cassidy J, Epelbaum R, ten Bokkel Huinink WW, Pavlidis N, Sorio R, Gamucci T, Wolff I, Te Velde A, Lan J, Verweij J. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 1996; 32A:2019-22. [PMID: 8943690 DOI: 10.1016/0959-8049(96)00226-2] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.
Collapse
Affiliation(s)
- L Y Dirix
- University Hospital of Antwerp, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
85
|
Pavlidis N, Hanauske AR, Gamucci T, Smyth J, Lehnert M, te Velde A, Lan J, Verweij J. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 1996; 7:529-31. [PMID: 8839911 DOI: 10.1093/oxfordjournals.annonc.a010645] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naïve patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bio-reductive alkylating indoloquinone. The drug was given at two different dose schedules by a single bolus i.v. injection: arm A 12 mg/m2 weekly and arm B 22 mg/m2 every three weeks. All together 185 courses were administered (145 in arm A and 40 in arm B). The major toxicity was reversible proteinuria more frequently occurring in the three-weekly schedule (arm A 34.5% vs. arm B 62.5%). Creatinine elevation, fluid retention and pericardial or pleural effusion were also recorded in a limited number of patients. Other common toxicities more frequent in the three-weekly administration were asthenia (21% vs. 35% of cycles), nausea (15% vs. 27.5% of cycles) and vomiting (5% vs. 17.5% of cycles). Toxicities were mainly of grade I and II. No responses have been observed. Five patients (26%) on arm A and eight (53%) on arm B experienced stable disease. These doses and schedules of EO9 do not yield activity in NSCLC.
Collapse
Affiliation(s)
- N Pavlidis
- University of Ioannina, Medical School, Oncology Section, Greece
| | | | | | | | | | | | | | | |
Collapse
|
86
|
Bruning P, Piccart M, Klijn J, Gamucci T, Kusenda Z, Roy J, Van Vreckem A, Paridaens R, IDBBC. PP-8-6 Paclitaxel (P) versus doxorublcin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): A randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84242-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
87
|
Ardizzoni A, Hansen H, Dombernowsky P, Kaplan S, Postmus P, Gamucci T, Schaefer B, Wanders J, Rweij J. 84 Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95336-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
88
|
Wanders J, Pavlidis N, Gamucci T, ten Bokkel Huinink W, Dirix L, Wolff I, Verweij J. 565 Phase II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95819-r] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
89
|
Gamucci T, Calabresi F, Zeuli M, Ceribelli A, Colucci G, Lomeo A, Maluta S, Battelli T, Bianco R, Brema E, Ghezzi P, Majoli I. 239 Prevention of anaemia in cancer patients treated with cisplatin-containing chemotherapy. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95497-t] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
90
|
Creemers GJ, Wanders J, Gamucci T, Vallentin S, Dirix LY, Schöffski P, Hudson I, Verweij J. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. Ann Oncol 1995; 6:844-6. [PMID: 8589027 DOI: 10.1093/oxfordjournals.annonc.a059328] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE This phase II study with the topoisomerase I inhibitor topotecan was performed to determine its clinical activity and toxicity in patients with metastatic or locally unresectable colorectal cancer. PATIENTS AND METHODS Topotecan 1.5 mg/m2 was administered intravenously by 30-minute infusion for 5 days. Fifty-nine patients entered the study, 2 were considered ineligible and 57 were evaluable for response and toxicity. RESULTS Partial response was obtained in 4 of 57 evaluable patients (7%). The median duration of the response was 11 months (range 9.3 to 12.2). This topotecan regimen was very well tolerated. A total of 290 courses were given, with a median of 4 courses per patient (range, 1 to 18). The major toxic effects were leuko- and neutropenia (91%), grade 3-4 in 48% and 79% of courses, respectively, but with only 2 infectious complications. Other side effects were grade 1 alopecia (77%) in 46%, nausea (35%), vomiting (10%), and maculo-papular rash (6%). CONCLUSIONS Topotecan administered as a daily-times-five regimen has only minor activity as a single-agent therapy in colorectal cancer.
Collapse
Affiliation(s)
- G J Creemers
- Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
91
|
Abstract
Biological response modifiers (BRMs) of current clinical interest may be divided into two categories: immunomodulating agents and colony stimulating factors (CSFs). The first are employed to potentiate the host defences towards the tumor but results have proved disappointing in non-small cell lung cancer (NSCLC). With regard to the second, the real dose increment which may be ascribed to CSFs is not sufficient to overcome chemoresistance of NSCLCs. CSFs can, however, reduce the hematologic toxicity of chemotherapy, which represents the most significant result.
Collapse
Affiliation(s)
- F Calabresi
- Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
| | | |
Collapse
|
92
|
Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 1993; 29A Suppl 2:S13-4. [PMID: 8398359 DOI: 10.1016/s0959-8049(05)80283-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- T Gamucci
- Department of Medical Oncology 1, Regina Elena Institute for Cancer Research, Rome, Italy
| | | | | | | | | |
Collapse
|